Seven Eight Capital, LP Fate Therapeutics Inc Transaction History

Seven Eight Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $1.9 Million - $4.6 Million	193,119 Added 936.83%	213,733 $2.16 Million
Q3 2022 Nov 10, 2022	BUY	$21.04 - $36.06 $433,718 - $743,340	20,614 New	20,614 $462,000
Q2 2021 Aug 13, 2021	SELL	$67.25 - $92.52 $1.04 Million - $1.43 Million	-15,503 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$38.09 - $100.95 $377,091 - $999,405	9,900 Added 176.69%	15,503 $1.41 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $170,387 - $226,921	5,603 New	5,603 $224,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.